Journal
CANCER BIOLOGY & MEDICINE
Volume -, Issue -, Pages -Publisher
CHINA ANTI-CANCER ASSOC
DOI: 10.20892/j.issn.2095-3941.2023.0108
Keywords
nuclear factor erythroid 2-related factor 2 (NRF2); ferroptosis; pyroptosis; KRAS; G12C allele-specific inhibitors; non -small cell lung cancer (NSCLC)
Categories
Ask authors/readers for more resources
Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several mechanisms, such as the upregulation of cystine transporter SLC7A11, the involvement of nuclear factor erythroid 2-related factor 2 (NRF2) and the activation of Extrinsic or Intrinsic apoptotic pathways, play important roles in the development of lung cancer. Moreover, the disruption of cystine availability and the involvement of exogenous cysteine/cystine and the transsulfuration pathway result in compromised CD8+ T cell function and evasion of immunotherapy, diminishing immune response and potentially reducing the effectiveness of immunotherapeutic interventions. Meanwhile, the breakthrough in KRAS G12C allele-specific inhibitors provides a potential therapeutic strategy for lung cancer treatment.
Lung oncogenesis relies on intracellular cysteine to overcome oxidative stress. Several tumor types, including non-small cell lung cancer (NSCLC), upregulate the system xc- cystine/glutamate antiporter (xCT) through overexpression of the cystine transporter SLC7A11, thus sustaining intracellular cysteine levels to support glutathione synthesis. Nuclear factor erythroid 2-related factor 2 (NRF2) serves as a master regulator of oxidative stress resistance by regulating SLC7A11, whereas Kelch-like ECH-associated protein (KEAP1) acts as a cytoplasmic repressor of the oxidative responsive transcription factor NRF2. Mutations in KEAP1/NRF2 and p53 induce SLC7A11 activation in NSCLC. Extracellular cystine is crucial in supplying the intracellular cysteine levels necessary to combat oxidative stress. Disruptions in cystine availability lead to iron-dependent lipid peroxidation, thus resulting in a type of cell death called ferroptosis. Pharmacologic inhibitors of xCT (either SLC7A11 or GPX4) induce ferroptosis of NSCLC cells and other tumor types. When cystine uptake is impaired, the intracellular cysteine pool can be sustained by the transsulfuration pathway, which is catalyzed by cystathionine-B-synthase (CBS) and cystathionine g-lyase (CSE). The involvement of exogenous cysteine/cystine and the transsulfuration pathway in the cysteine pool and downstream metabolites results in compromised CD8+ T cell function and evasion of immunotherapy, diminishing immune response and potentially reducing the effectiveness of immunotherapeutic interventions. Pyroptosis is a previously unrecognized form of regulated cell death. In NSCLCs driven by EGFR, ALK, or KRAS, selective inhibitors induce pyroptotic cell death as well as apoptosis. After targeted therapy, the mitochondrial intrinsic apoptotic pathway is activated, thus leading to the cleavage and activation of caspase-3. Consequently, gasdermin E is activated, thus leading to permeabilization of the cytoplasmic membrane and cell-lytic pyroptosis (indicated by characteristic cell membrane ballooning). Breakthroughs in KRAS G12C allele-specific inhibitors and potential mechanisms of resistance are also discussed herein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available